Английская Википедия:Acetaminophen Autism Mass Tort

Материал из Онлайн справочника
Версия от 19:55, 28 декабря 2023; EducationBot (обсуждение | вклад) (Новая страница: «{{Английская Википедия/Панель перехода}} {{Orphan|date=November 2022}} On October 5, 2022, the U.S. Judicial Panel on Multidistrict Litigation (JPML) transferred<ref>{{Cite web |date=2022-10-05 |title=TRANSFER ORDER |url=https://www.jpml.uscourts.gov/sites/jpml/files/MDL-3043-Initial-Transfer-Order-9-22.pdf |access-date=2022-11-21 |website=UNITED STATES JUDICIAL PANEL on MULTIDISTRICT LITIGATION}}</ref> some 66 autism...»)
(разн.) ← Предыдущая версия | Текущая версия (разн.) | Следующая версия → (разн.)
Перейти к навигацииПерейти к поиску

Шаблон:Orphan On October 5, 2022, the U.S. Judicial Panel on Multidistrict Litigation (JPML) transferred[1] some 66 autism and ADHD lawsuits[2] to Senior District Judge Denise Cote in the Southern District of New York, thus consolidating all such acetominophen birth defect cases in a mass tort.[3] The case specifically concerns the lack of warning regarding in utero use. On 2022-11-19 Judge Cote among other matters ruled against Walmart's preemption argument (which is often raised in pharmaceutical mass tort cases). Judge Cote likewise ruled against Johnson & Johnson in April 2023.[4] Given the significant media attention and advertising the class action has been receiving, the number of plaintiffs is widely anticipated to considerably increase.[5][6]

The case was thrown out December 18, 2023,[7] with Judge Cote writing "“The unstructured approach adopted by the plaintiffs’ experts permitted cherry-picking, allowed a results-driven analysis, and obscured the complexities, inconsistencies, and weaknesses in the underlying data..."[8]

References

Шаблон:ReflistШаблон:Autism-stubШаблон:US-case-law-stubШаблон:Portal